Анализа корелације серумског ЛАП-а, ГДГФ-а и феритина у прогнози акутне мијелоидне леукемије
Серумски ЛАП, ГДГФ и феритин у прогнози АМЛ-а
Sažetak
Objective To look into the correlation analysis between blood levels of Latency associated peptide (LAP), Glioma-derived growth factor (GDGF), Ferritin, Neutrophil/Lymphocyte ratio, and Albumin/Fibrinogen ratio and the prognosis of patients with acute myeloid leukemia (AML).
Methods The study group consisted of 384 AML patients who were hospitalized to the hospital between May 2022 and October 2024, whereas the control group was made up of 192 healthy people who were examined physically while they were there. The levels of serum LAP, GDGF, and Ferritin and the Neutrophil/Lymphocyte ratio and Albumin/Fibrinogen ratio were compared. Following their discharge, the study group's participants were monitored for a total of 12 months. Patients having a favorable prognosis and those with a bad prognosis were divided into two groups. The factors predicting a poor prognosis in AML patients were examined using multivariate logistic regression and a comparison of the clinical data from the two groups. Receiver operating characteristic (ROC) curves were developed to evaluate the predictive significance of LAP, GDGF, Neutrophil/Lymphocyte ratio, Albumin/Fibrinogen ratio, and Ferritin for a poor prognosis in AML patients.
Results The GDGF level, Ferritin, Neutrophil/Lymphocyte ratio, and Albumin/ Fibrinogen ratio were all higher than those in the control group (P<0.05), although the study group's serum LAP level was lower (P<0.05). Among the AML patients, 116 had a poor prognosis (poor prognosis group), and 268 had a good prognosis (good prognosis group). The group with a bad prognosis had lower levels of GDGF, Ferritin, Neutrophil/Lymphocyte ratio, and Albumin/Fibrinogen ratio (P<0.05), although the group with a good prognosis had greater levels of serum LAP (P<0.05). Multivariate logistic regression analysis showed that elevated serum LAP levels were independent protective factors for poor prognosis in AML patients (P<0.05), while elevated serum GDGF and Ferritin levels, along with elevated Neutrophil/Lymphocyte ratios and Albumin/Fibrinogen ratios, were independent risk factors for poor prognosis in AML patients (P<0.05). According to the ROC curve study, the areas under the curve (AUCs) of LAP, GDGF, Ferritin, the Neutrophil/Lymphocyte ratio, and the Albumin/Fibrinogen ratio for forecasting a poor prognosis in AML patients were 0.747, 0.811, 0.804, 0.783, and 0.845, respectively.
Conclusion Serum LAP levels are decreased in AML patients, whereas GDGF, Ferritin, Neutrophil/Lymphocyte ratio and Albumin/Fibrinogen ratio levels are increased. Additionally, each of the aforementioned signs has some prediction value for the poor prognosis of individuals with AML and is an independent influencing factor.
Reference
Weinberg OK, Porwit A, Orazi A, Hasserjian RP, Foucar K, Duncavage EJ, Arber DA. The International Consensus Classification of acute myeloid leukemia. Virchows Arch. 2023 Jan;482(1):27-37. doi: 10.1007/s00428-022-03430-4. Epub 2022 Oct 20. PMID: 36264379.
Kayser S, Levis MJ. The clinical impact of the molecular landscape of acute myeloid leukemia. Hematologica. 2023 Feb 1;108(2):308-320. doi: 10.3324/hematol.2022.280801. PMID: 36722402; PMCID: PMC9890016.
Alhajahjeh A, Bewersdorf JP, Bystrom RP, Zeidan AM, Shimony S, Stahl M. Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome. Leuk Lymphoma. 2024 Nov;65(11):1541-1551. doi: 10.1080/10428194.2024.2367040. Epub 2024 Jul 4. PMID: 38962996.
Chen EC, Shimony S, Luskin MR, Stone RM. Biology and Management of Acute Myeloid Leukemia With Mutated NPM1. Am J Hematol. 2025 Apr;100(4):652-665. doi: 10.1002/ajh.27600. Epub 2025 Feb 4. PMID: 39901865.
Harrigan AM, Trottier AM. Hereditary acute myeloid leukemia associated with C-terminal CEBPA germline variants. Fam Cancer. 2023 Jul;22(3):331-339. doi: 10.1007/s10689-023-00329-0. Epub 2023 Mar 6. PMID: 36879149.
Gao Q, Shen K, Xiao M. TET2 mutation in acute myeloid leukemia: biology, clinical significance, and therapeutic insights. Clin Epigenetics. 2024 Nov 9;16(1):155. doi: 10.1186/s13148-024-01771-2. PMID: 39521964; PMCID: PMC11550532.
Babakhanlou R, Ravandi-Kashani F. Nonintensive acute myeloid leukemia therapies for older patients. Expert Rev Hematol. 2023 Mar;16(3):171-180. doi: 10.1080/17474086.2023.2184342. Epub 2023 Mar 2. PMID: 36864772.
Schlenk RF. Acute myeloid leukemia: introduction to a series highlighting progress and ongoing challenges. Hematologica. 2023 Feb 1;108(2):306-307. doi: 10.3324/hematol.2022.280803. PMID: 36722401; PMCID: PMC9890027.
Zha C, Yang X, Yang J, Zhang Y, Huang R. Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies. Ann Hematol. 2024 Dec;103(12):4883-4899. doi: 10.1007/s00277-024-06117-9. Epub 2024 Nov 28. PMID: 39607487.
Yuan J, He R, Alkhateeb HB. Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations. Curr Hematol Malig Rep. 2023 Oct;18(5):121-129. doi: 10.1007/s11899-023-00699-3. Epub 2023 Jun 1. PMID: 37261703; PMCID: PMC10484814.
Chaudhary S, Chaudhary P, Ahmad F, Arora N. Acute Myeloid Leukemia and Next-Generation Sequencing Panels for Diagnosis: A Comprehensive Review. J Pediatr Hematol Oncol. 2024 Apr 1;46(3):125-137. doi: 10.1097/MPH.0000000000002840. Epub 2024 Feb 29. PMID: 38447075; PMCID: PMC10956683.
Ji RJ, Cao GH, Zhao WQ, Wang MY, Gao P, Zhang YZ, Wang XB, Qiu HY, Chen DD, Tong XH, Duan M, Yin H, Zhang Y. Epitope prime editing shields hematopoietic cells from CD123 immunotherapy for acute myeloid leukemia. Cell Stem Cell. 2024 Nov 7;31(11):1650-1666.e8. doi: 10.1016/j.stem.2024.09.003. Epub 2024 Sep 30. PMID: 39353428.
Tien FM, Hou HA. CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment. Int J Hematol. 2024 Nov;120(5):541-547. doi: 10.1007/s12185-024-03773-5. Epub 2024 Apr 26. PMID: 38671183.
Lucas F, Hergott CB. Advances in Acute Myeloid Leukemia Classification, Prognostication and Monitoring by Flow Cytometry. Clin Lab Med. 2023 Sep;43(3):377-398. doi: 10.1016/j.cll.2023.04.005. Epub 2023 Jun 11. PMID: 37481318.
Chean D, Maillard A, Benattia A, Fodil S, Azoulay E. Acute respiratory failure in adult patients with acute myeloid leukemia. Expert Rev Respir Med. 2024 Dec;18(12):963-974. doi: 10.1080/17476348.2024.2433554. Epub 2024 Nov 25. PMID: 39587388.
Zheng S, Tong Y, Yang L, Chen J, Tan Y. The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment. Ann Hematol. 2024 Dec;103(12):5019-5033. doi: 10.1007/s00277-024-06050-x. Epub 2024 Oct 29. PMID: 39467855.
Larrue C, Mouche S, Angelino P, Sajot M, Birsen R, Kosmider O, Mckee T, Vergez F, Recher C, Mas VM, Gu Q, Xu J, Tsantoulis P, Sarry JE, Tamburini J. Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo models. Sci Transl Med. 2024 Jul 24;16(757):eadk1731. doi: 10.1126/scitranslmed.adk1731. Epub 2024 Jul 24. PMID: 39047119.
Bidet A, Quessada J, Cuccuini W, Decamp M, Lafage-Pochitaloff M, Luquet I, Lefebvre C, Tueur G; Groupe Francophone de Cytogénétique Hématologique (GFCH). Cytogenetics in the management of acute myeloid leukemia and histiocytic/dendritic cell neoplasms: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH). Curr Res Transl Med. 2023 Oct-Dec;71(4):103421. doi: 10.1016/j.retram.2023.103421. Epub 2023 Oct 16. PMID: 38016419.
Tsutsumi E, Yamasaki K, Nakano Y, Takagi M, Hara J. Acute myeloid leukemia post RAS-associated autoimmune leukoproliferative disease. Pediatr Int. 2023 Jan-Dec;65(1):e15521. doi: 10.1111/ped.15521. PMID: 36897112.
Bruserud Ø, Selheim F, Hernandez-Valladares M, Reikvam H. Monocytic Differentiation in Acute Myeloid Leukemia Cells: Diagnostic Criteria, Biological Heterogeneity, Mitochondrial Metabolism, Resistance to and Induction by Targeted Therapies. Int J Mol Sci. 2024 Jun 8;25(12):6356. doi: 10.3390/ijms25126356. PMID: 38928061; PMCID: PMC11203697.
Bystrom R, Levis MJ. An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape. Curr Oncol Rep. 2023 Apr;25(4):369-378. doi: 10.1007/s11912-023-01389-2. Epub 2023 Feb 18. PMID: 36808557.
Pereira MP, Herrity E, Kim DDH. TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches. Ann Hematol. 2024 Apr;103(4):1049-1067. doi: 10.1007/s00277-023-05462-5. Epub 2023 Sep 28. PMID: 37770618.
Herold T. Update Akute Myeloische Leukämie: Zahlreiche kleine und große Veränderungen in den letzten Jahren [Update Acute Myeloid Leukemia: Numerous small and large changes in recent years]. Dtsch Med Wochenschr. 2023 Apr;148(8):429. German. doi: 10.1055/a-1855-9239. Epub 2023 Mar 29. PMID: 36990114.
Liu M, Yang M, Qi Y, Ma Y, Guo Q, Guo L, Liu C, Liu W, Xiao L, Yang Y. Immunosuppressive cells in acute myeloid leukemia: mechanisms and therapeutic target. Front Immunol. 2025 Jul 23;16:1627161. doi: 10.3389/fimmu.2025.1627161. PMID: 40771826; PMCID: PMC12325080.
Canichella M, Molica M, Mazzone C, de Fabritiis P. Maintenance Therapy Post-Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Curr Oncol. 2024 Oct 10;31(10):6050-6060. doi: 10.3390/curroncol31100451. PMID: 39451755; PMCID: PMC11506619.
Zhao J, Qiao G, Tong L, Feng X, Mao X, Huang J, Sun Y. Acute myeloid leukemia with blue‒green neutrophilic inclusions have different outcomes: two cases and review of the literature. Clin Chem Lab Med. 2023 Dec 29;62(6):e140-e143. doi: 10.1515/cclm-2023-1065. PMID: 38153144.
Santos de Macedo BG, Albuquerque de Melo M, Pereira-Martins DA, Machado-Neto JA, Traina F. An updated outlook on autophagy mechanism and how it supports acute myeloid leukemia maintenance. Biochim Biophys Acta Rev Cancer. 2024 Nov;1879(6):189214. doi: 10.1016/j.bbcan.2024.189214. Epub 2024 Nov 6. PMID: 39515545.
Tian Z, Octaviani S, Huang J. Unraveling therapeutic targets in acute myeloid leukemia through multiplexed genome editing CRISPR screening. Expert Opin Ther Targets. 2023 Jul-Dec;27(12):1173-1176. doi: 10.1080/14728222.2023.2293751. Epub 2023 Dec 30. PMID: 38069633; PMCID: PMC11619811.
Jain AG, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S, Kuykendall A, Chan O, Sweet K, Lancet JE, Padron E, Sallman DA, Komrokji R. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia. Haematologica. 2024 Jul 1;109(7):2157-2164. doi: 10.3324/haematol.2023.283661. PMID: 38299605; PMCID: PMC11215361.
Fang Z, Ding H, Han J, Fu L, Jin J, Feng W. Functions of N6-methyladenosine (m6A) RNA modifications in acute myeloid leukemia. J Leukoc Biol. 2024 Oct 1;116(4):662-671. doi: 10.1093/jleuko/qiae106. PMID: 38721720.
Calabria S, Ronconi G, Dondi L, Piccinni C, Pedrini A, Esposito I, Addesi A, Rossi G, Ferrara F, Venditti A, Martini N. Acute myeloid leukemia: Incidence, transplantation and survival through Italian administrative healthcare data. Tumori. 2023 Oct;109(5):496-503. doi: 10.1177/03008916231153698. Epub 2023 Mar 9. PMID: 36896466.
Sva prava zadržana (c) 2026 Naixia Ma, Rui Zhou, Yaqi Ge, Yahong Huan
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.